<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249274</url>
  </required_header>
  <id_info>
    <org_study_id>1005006793</org_study_id>
    <secondary_id>R21DA029914</secondary_id>
    <nct_id>NCT01249274</nct_id>
  </id_info>
  <brief_title>Progesterone for Postpartum Cocaine Relapse</brief_title>
  <official_title>Progesterone for Postpartum Cocaine Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a placebo-controlled, randomized clinical trial that would enroll
      50 postpartum women with a history of cocaine abuse or dependence to assess whether
      progesterone (100mgs twice daily) decreases postpartum cocaine use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To evaluate whether postpartum women with a history of cocaine abuse or
      dependence use less cocaine if they are randomized to progesterone than placebo.

      Hypothesis 1: Compared to women who are randomized to placebo, those assigned to progesterone
      will use less cocaine as measured by urine toxicology results and self-reported days of use.

      Specific aim 2: To obtain information about the safety and tolerability of progesterone
      treatment in the postpartum period.

      Hypothesis 2: Side effects for progesterone will be similar to those of placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Number of Days Per Week of Cocaine Use</measure>
    <time_frame>Weekly measurements, Baseline to 12 weeks</time_frame>
    <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week via substance use calendar.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days of Cocaine Use Between 12 Week Visits &amp; the 3 Month Follow up</measure>
    <time_frame>baseline, end of trial (week 12), 3-month post-trial follow-up</time_frame>
    <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week during the trial period and during 3 month follow up using the substance use calendar</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Positive Urine Samples Per Week</measure>
    <time_frame>weekly measurements, baseline to 12 weeks</time_frame>
    <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Positive Urine Samples Per Week</measure>
    <time_frame>baseline, end of trial (week 12) and 3-month post-trial follow-up</time_frame>
    <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Comparison of Adverse Events Between Women in Placebo and Progesterone Group</measure>
    <time_frame>12 weeks postpartum</time_frame>
    <description>To obtain information about the safety and tolerability of progesterone treatment in the postpartum period, women were queried at every visit about onset of adverse events, their seriousness, and their relatedness to study medication. Such data was monitored in SAETRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Craving (Measured Weekly Using CCQ-Brief)</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>CCQ-Brief is a ten-item questionnaire developed from the 45-item CCQ. Each item is scored on a visual analogue scale ranging from 1-7, and items are averaged to yield a score from 1 to 7. Higher scores indicate stronger cocaine cravings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression (Measured Weekly Using Edinburgh Postnatal Depression Scale (EPDS))</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>EPDS scores were measured to detect depression as a possible adverse event and compare scores between the two groups. The scale consists of 10 items. Each item is scored from 0 to 3, and the 10 items are summed to calculate a total score with a possible range of 0 to 30 and higher scores indicating more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary Progesterone Concentrations</measure>
    <time_frame>week 2, week 6, week 10, week 12</time_frame>
    <description>A comparison of salivary progesterone concentrations across all samples for all timepoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cocaine Abuse</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo pills to be taken twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mgs progesterone twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>100mgs progesterone twice daily</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>prometrium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo pills to be taken twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gravidas (women who delivered a baby in the past 12 weeks) who are 18 or older are
             eligible to participate.

          -  Women must meet diagnostic criteria for abuse or dependence of cocaine in the
             six-months prior to conception or during pregnancy.

          -  Women who abuse other illicit substances or alcohol would also be eligible as long as
             cocaine was their primary drug of abuse. If women are also opiate dependent, they must
             be undergoing treatment with methadone or buprenorphine. While we propose to target
             cocaine we will also monitor the ability of women with polysubstance use to maintain
             abstinence from substances other than cocaine.

        Exclusion Criteria:

        Women will be ineligible for the trial if they:

          1. have a history of major medical illnesses including liver diseases, suspected or known
             malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or
             bleeding disorders, heart disease, diabetes, history of stroke or other medical
             conditions that the physician investigator deems as contraindicated for participation
             in the study;

          2. have a known allergy to progesterone or peanuts (vehicle for micronized progesterone);

          3. speak a language other than English;

          4. are planning on moving out of the area in the first six months after delivery;

          5. are unable to understand the study or are unable to provide informed consent;

          6. are currently undergoing treatment with another pharmacological agent for substance
             abuse treatment (with the exception of methadone or buprenorphine as above);

          7. have pending incarceration;

          8. are currently incarcerated;

          9. are using another progestin;

         10. are unwilling to accept randomization;

         11. are unwilling to use a barrier method of birth control for the duration of the study
             to ensure that they will not become pregnant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly A Yonkers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehmet Sofuoglu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://researchforher.com</url>
    <description>Research site webpage</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2010</study_first_posted>
  <results_first_submitted>January 5, 2016</results_first_submitted>
  <results_first_submitted_qc>October 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Kimberly Yonkers</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cocaine abuse</keyword>
  <keyword>cocaine dependence</keyword>
  <keyword>postpartum period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data request should be made to the PI</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>On-site clinic screening assessments were performed in three obstetrics clinic associated with the Yale New Haven Hospital System in New Haven, CT, USA. Study referrals were accepted from the New Haven area. Both post-partum and pregnant women were screened. Screenings began in October of 2010 and finished in February of 2013.</recruitment_details>
      <pre_assignment_details>75 women were scheduled for intake, but 24 did not complete intake interview and 1 was ineligible for randomisation because of a medical issue. The first 50 eligible women were randomly assigned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
        </group>
        <group group_id="P2">
          <title>Progesterone</title>
          <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">all 25 were included in intention-to-treat and safety analyses</participants>
                <participants group_id="P2" count="25">all 25 were included in intention-to-treat and safety analyses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment &amp; Post Trial Visit</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Post Trial Visit But Not tx</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received inpatient substance treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 25 in each study group were included in intention-to-treat and safety analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
        </group>
        <group group_id="B2">
          <title>Progesterone</title>
          <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="6.3"/>
                    <measurement group_id="B2" value="30.5" spread="4.5"/>
                    <measurement group_id="B3" value="31.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than high shool</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-high school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Married or cohabitating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>In paid employment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not in paid employment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weeks post partum</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="5.1"/>
                    <measurement group_id="B2" value="3.6" spread="4.6"/>
                    <measurement group_id="B3" value="3.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime cocaine use (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="7.2"/>
                    <measurement group_id="B2" value="6.2" spread="4.2"/>
                    <measurement group_id="B3" value="7.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first cocaine use (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread="6.3"/>
                    <measurement group_id="B2" value="19.2" spread="4.0"/>
                    <measurement group_id="B3" value="19.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>births</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="1.6"/>
                    <measurement group_id="B2" value="2.1" spread="1.4"/>
                    <measurement group_id="B3" value="2.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EPDS score at intake</title>
          <description>The Edinburgh Postnatal Depression scale measures depression and has 10 items with range of 0-30. Higher scores indicate more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="6.7"/>
                    <measurement group_id="B2" value="11.2" spread="7.2"/>
                    <measurement group_id="B3" value="11.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline cocaine use (days per week)</title>
          <description>Baseline cocaine use (days of use per week, averaged across 4 weeks prior to baseline, maximum value=7 days)</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.41" spread=".91"/>
                    <measurement group_id="B2" value="1.15" spread="3.84"/>
                    <measurement group_id="B3" value="1.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Not using cocaine at intake</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not using cocaine at intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Using cocaine at intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Methadone maintained</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Using methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not using methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any lifetime major depressive episode</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of MDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No history of MDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Social phobia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of social phobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No history of social phobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obsessive compulsive disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Generalized anxiety disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-traumatic stress disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Days Per Week of Cocaine Use</title>
        <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week via substance use calendar.</description>
        <time_frame>Weekly measurements, Baseline to 12 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days Per Week of Cocaine Use</title>
          <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week via substance use calendar.</description>
          <population>intent-to-treat</population>
          <units>number of days per week of cocaine use</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.91"/>
                    <measurement group_id="O2" value="1.15" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.88"/>
                    <measurement group_id="O2" value="1.01" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.89"/>
                    <measurement group_id="O2" value="0.89" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.91"/>
                    <measurement group_id="O2" value="0.78" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.94"/>
                    <measurement group_id="O2" value="0.68" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.02"/>
                    <measurement group_id="O2" value="0.60" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.13"/>
                    <measurement group_id="O2" value="0.53" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.30"/>
                    <measurement group_id="O2" value="0.46" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.37"/>
                    <measurement group_id="O2" value="0.41" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.55"/>
                    <measurement group_id="O2" value="0.36" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.68"/>
                    <measurement group_id="O2" value="0.31" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.91"/>
                    <measurement group_id="O2" value="0.28" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="2.11"/>
                    <measurement group_id="O2" value="0.24" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Generalized Estimating Equation</method>
            <method_desc>Negative binomial distribution, log link, and first-order autoregressive covariance structure</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>Estimated value is the risk ratio estimate for the treatment x time interaction term. Time was treated as a continuous variable and progesterone was the reference group for the treatment variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days of Cocaine Use Between 12 Week Visits &amp; the 3 Month Follow up</title>
        <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week during the trial period and during 3 month follow up using the substance use calendar</description>
        <time_frame>baseline, end of trial (week 12), 3-month post-trial follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Cocaine Use Between 12 Week Visits &amp; the 3 Month Follow up</title>
          <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week during the trial period and during 3 month follow up using the substance use calendar</description>
          <population>intent-to-treat</population>
          <units>days of cocaine use between visits</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5200" lower_limit="0.1419" upper_limit="1.9062"/>
                    <measurement group_id="O2" value="1.6800" lower_limit="0.5983" upper_limit="4.7171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Trial (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2860" lower_limit="0.1237" upper_limit="0.6609"/>
                    <measurement group_id="O2" value="0.05550" lower_limit="0.009978" upper_limit="0.3087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Month Post-Trial Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8472" lower_limit="5.3751" upper_limit="30.7066"/>
                    <measurement group_id="O2" value="1.3659" lower_limit="0.2618" upper_limit="7.1263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We calculated that a sample size of 50 women would have 80% power to detect a significant (p&lt;0.05) difference between groups if the effect size for the primary outcome was large.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Generalized Estimating Equation</method>
            <method_desc>Negative binomial distribution, log link, and first-order autoregressive covariance structure</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>30.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.18</ci_lower_limit>
            <ci_upper_limit>290.04</ci_upper_limit>
            <estimate_desc>Estimated value is RR for treatment*time interaction for placebo at 3-mo post-trial follow-up. Time treated as a 3-level categorical variable; week 0 (ref), week 12 &amp; 3-month post-trial follow-up. Treatment variable reference group was progesterone.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Negative binomial distribution, log link, and first-order autoregressive covariance structure</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>16.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>235.52</ci_upper_limit>
            <estimate_desc>Estimated value is RR for treatment*time interaction term for placebo at week 12. Time was treated as a 3-level categorical variable; week 0 (ref), week 12 and 3-month post-trial follow-up. Treatment variable reference group was progesterone.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Positive Urine Samples Per Week</title>
        <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
        <time_frame>weekly measurements, baseline to 12 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Positive Urine Samples Per Week</title>
          <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
          <population>intent-to-treat</population>
          <units>proportion of positive urines per week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2645" lower_limit="0.1278" upper_limit="0.4688"/>
                    <measurement group_id="O2" value="0.1990" lower_limit="0.0882" upper_limit="0.3893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2667" lower_limit="0.1366" upper_limit="0.4554"/>
                    <measurement group_id="O2" value="0.2006" lower_limit="0.0928" upper_limit="0.3810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2689" lower_limit="0.1448" upper_limit="0.4443"/>
                    <measurement group_id="O2" value="0.2022" lower_limit="0.0969" upper_limit="0.3745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2712" lower_limit="0.1519" upper_limit="0.4360"/>
                    <measurement group_id="O2" value="0.2038" lower_limit="0.1003" upper_limit="0.3702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2734" lower_limit="0.1576" upper_limit="0.4309"/>
                    <measurement group_id="O2" value="0.2054" lower_limit="0.1029" upper_limit="0.3681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2757" lower_limit="0.1613" upper_limit="0.4296"/>
                    <measurement group_id="O2" value="0.2071" lower_limit="0.1047" upper_limit="0.3685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2780" lower_limit="0.1629" upper_limit="0.4323"/>
                    <measurement group_id="O2" value="0.2087" lower_limit="0.1054" upper_limit="0.3714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2803" lower_limit="0.1623" upper_limit="0.4390"/>
                    <measurement group_id="O2" value="0.2104" lower_limit="0.1051" upper_limit="0.3768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2826" lower_limit="0.1597" upper_limit="0.4494"/>
                    <measurement group_id="O2" value="0.2121" lower_limit="0.1038" upper_limit="0.3847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2849" lower_limit="0.1553" upper_limit="0.4633"/>
                    <measurement group_id="O2" value="0.2138" lower_limit="0.1017" upper_limit="0.3949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2872" lower_limit="0.1496" upper_limit="0.4799"/>
                    <measurement group_id="O2" value="0.2154" lower_limit="0.0989" upper_limit="0.4071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2895" lower_limit="0.1429" upper_limit="0.4989"/>
                    <measurement group_id="O2" value="0.2171" lower_limit="0.0956" upper_limit="0.4213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2918" lower_limit="0.1356" upper_limit="0.5198"/>
                    <measurement group_id="O2" value="0.2189" lower_limit="0.0918" upper_limit="0.4372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We calculated that a sample size of 50 women would have 80% power to detect a significant (p&lt;0.05) difference between groups if the effect size for the primary outcome was large.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Estimated value is the risk ratio for the treatment x time interaction term. Time was treated as a continuous variable and progesterone was the reference group for treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Positive Urine Samples Per Week</title>
        <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
        <time_frame>baseline, end of trial (week 12) and 3-month post-trial follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Positive Urine Samples Per Week</title>
          <description>Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.</description>
          <population>intent-to-treat</population>
          <units>proportion of positive urines per week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2400" lower_limit="0.1120" upper_limit="0.4416"/>
                    <measurement group_id="O2" value="0.1582" lower_limit="0.0559" upper_limit="0.3733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3173" lower_limit="0.1606" upper_limit="0.5303"/>
                    <measurement group_id="O2" value="0.1904" lower_limit="0.0758" upper_limit="0.4028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month post-trial follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3952" lower_limit="0.2189" upper_limit="0.6037"/>
                    <measurement group_id="O2" value="0.2246" lower_limit="0.0852" upper_limit="0.4740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We calculated that a sample size of 50 women would have 80% power to detect a significant (p&lt;0.05) difference between groups if the effect size for the primary outcome was large.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Generalized Estimating Equation</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
            <estimate_desc>Estimated value is RR for treatment*time interaction for placebo at 3-mo post-trial follow-up. Time treated as a 3-level categorical variable; week 0 (ref), week 12 &amp; 3-month post-trial follow-up. Treatment variable reference group was progesterone.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Generalized Estimating Equation</method>
            <method_desc>Negative binomial distribution, log link, and first-order autoregressive covariance structure</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
            <estimate_desc>Estimated value is RR for treatment*time interaction for placebo at week 12. Time was treated as a 3-level categorical variable; week 0 (ref), week 12 &amp; 3-month post-trial follow-up. Treatment variable reference group was progesterone.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Comparison of Adverse Events Between Women in Placebo and Progesterone Group</title>
        <description>To obtain information about the safety and tolerability of progesterone treatment in the postpartum period, women were queried at every visit about onset of adverse events, their seriousness, and their relatedness to study medication. Such data was monitored in SAETRS.</description>
        <time_frame>12 weeks postpartum</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comparison of Adverse Events Between Women in Placebo and Progesterone Group</title>
          <description>To obtain information about the safety and tolerability of progesterone treatment in the postpartum period, women were queried at every visit about onset of adverse events, their seriousness, and their relatedness to study medication. Such data was monitored in SAETRS.</description>
          <population>intent-to-treat</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1030</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Craving (Measured Weekly Using CCQ-Brief)</title>
        <description>CCQ-Brief is a ten-item questionnaire developed from the 45-item CCQ. Each item is scored on a visual analogue scale ranging from 1-7, and items are averaged to yield a score from 1 to 7. Higher scores indicate stronger cocaine cravings.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving (Measured Weekly Using CCQ-Brief)</title>
          <description>CCQ-Brief is a ten-item questionnaire developed from the 45-item CCQ. Each item is scored on a visual analogue scale ranging from 1-7, and items are averaged to yield a score from 1 to 7. Higher scores indicate stronger cocaine cravings.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5630" lower_limit="1.2953" upper_limit="1.8860"/>
                    <measurement group_id="O2" value="1.6752" lower_limit="1.3609" upper_limit="2.0620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5456" lower_limit="1.3073" upper_limit="1.8275"/>
                    <measurement group_id="O2" value="1.6532" lower_limit="1.3616" upper_limit="2.0073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5285" lower_limit="1.3161" upper_limit="1.7751"/>
                    <measurement group_id="O2" value="1.6316" lower_limit="1.3594" upper_limit="1.9583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5115" lower_limit="1.3205" upper_limit="1.7301"/>
                    <measurement group_id="O2" value="1.6102" lower_limit="1.3536" upper_limit="1.9154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4947" lower_limit="1.3189" upper_limit="1.6939"/>
                    <measurement group_id="O2" value="1.5891" lower_limit="1.3438" upper_limit="1.8791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4781" lower_limit="1.3097" upper_limit="1.6681"/>
                    <measurement group_id="O2" value="1.5683" lower_limit="1.3297" upper_limit="1.8497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4616" lower_limit="1.2925" upper_limit="1.6530"/>
                    <measurement group_id="O2" value="1.5478" lower_limit="1.3111" upper_limit="1.8271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4454" lower_limit="1.2678" upper_limit="1.6478"/>
                    <measurement group_id="O2" value="1.5275" lower_limit="1.2883" upper_limit="1.8111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4293" lower_limit="1.2374" upper_limit="1.6510"/>
                    <measurement group_id="O2" value="1.5075" lower_limit="1.2619" upper_limit="1.8009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4134" lower_limit="1.2032" upper_limit="1.6604"/>
                    <measurement group_id="O2" value="1.4877" lower_limit="1.2325" upper_limit="1.7957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3977" lower_limit="1.1668" upper_limit="1.6744"/>
                    <measurement group_id="O2" value="1.4682" lower_limit="1.2010" upper_limit="1.7949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3822" lower_limit="1.1292" upper_limit="1.6919"/>
                    <measurement group_id="O2" value="1.4490" lower_limit="1.1681" upper_limit="1.7975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3668" lower_limit="1.0914" upper_limit="1.7118"/>
                    <measurement group_id="O2" value="1.4300" lower_limit="1.1342" upper_limit="1.8030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9116</p_value>
            <method>Generalized Estimating Equation</method>
            <method_desc>Gamma distribution, logit link, 1st-order autoregressive covariance structure; p-value is for chi-sq (df=1) for type 3 GEE analysis score statistic</method_desc>
            <param_type>Score Statistic For Type 3 GEE Analysis</param_type>
            <param_value>0.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Estimated value is chi-sq (df=1) for type 3 GEE analysis score statistic for week*treatment interaction term.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression (Measured Weekly Using Edinburgh Postnatal Depression Scale (EPDS))</title>
        <description>EPDS scores were measured to detect depression as a possible adverse event and compare scores between the two groups. The scale consists of 10 items. Each item is scored from 0 to 3, and the 10 items are summed to calculate a total score with a possible range of 0 to 30 and higher scores indicating more severe depression.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Depression (Measured Weekly Using Edinburgh Postnatal Depression Scale (EPDS))</title>
          <description>EPDS scores were measured to detect depression as a possible adverse event and compare scores between the two groups. The scale consists of 10 items. Each item is scored from 0 to 3, and the 10 items are summed to calculate a total score with a possible range of 0 to 30 and higher scores indicating more severe depression.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.84" spread="1.37"/>
                    <measurement group_id="O2" value="11.08" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="1.37"/>
                    <measurement group_id="O2" value="8.61" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="1.19"/>
                    <measurement group_id="O2" value="6.65" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="1.04"/>
                    <measurement group_id="O2" value="6.95" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" spread="1.60"/>
                    <measurement group_id="O2" value="6.62" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.60" spread="1.54"/>
                    <measurement group_id="O2" value="6.62" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="1.52"/>
                    <measurement group_id="O2" value="7.24" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" spread="1.71"/>
                    <measurement group_id="O2" value="6.53" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="1.64"/>
                    <measurement group_id="O2" value="6.16" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.24" spread="1.70"/>
                    <measurement group_id="O2" value="6.68" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" spread="1.69"/>
                    <measurement group_id="O2" value="6.64" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="1.43"/>
                    <measurement group_id="O2" value="6.85" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.38" spread="1.71"/>
                    <measurement group_id="O2" value="6.60" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-month post trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="1.43"/>
                    <measurement group_id="O2" value="7.21" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Salivary Progesterone Concentrations</title>
        <description>A comparison of salivary progesterone concentrations across all samples for all timepoints</description>
        <time_frame>week 2, week 6, week 10, week 12</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary Progesterone Concentrations</title>
          <description>A comparison of salivary progesterone concentrations across all samples for all timepoints</description>
          <population>intent-to-treat</population>
          <units>pg/ml of salivary progesterone</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.94" spread="135.30"/>
                    <measurement group_id="O2" value="797.26" spread="1004.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.38" spread="237.94"/>
                    <measurement group_id="O2" value="1580.95" spread="1963.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.30" spread="72.31"/>
                    <measurement group_id="O2" value="1771.07" spread="3139.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.04" spread="288.51"/>
                    <measurement group_id="O2" value="866.10" spread="1044.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Relapse to Cocaine Use During Treatment Period</title>
        <description>Post-hoc sensitivity test to compare hazard of relapse to cocaine use between two treatment groups among participants (n=41) who did not report using cocaine at intake.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse to Cocaine Use During Treatment Period</title>
          <description>Post-hoc sensitivity test to compare hazard of relapse to cocaine use between two treatment groups among participants (n=41) who did not report using cocaine at intake.</description>
          <population>intent-to-treat</population>
          <units>participants who relapsed to cocaine use</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>4.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>20.50</ci_upper_limit>
            <estimate_desc>Ratio presented is for placebo versus progesterone</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Relapse to Cocaine Use During Treatment Period or 3 Months Post Treatment</title>
        <description>Post-hoc sensitivity test to compare hazard of relapse to cocaine use between two treatment groups among participants (n=41) who did not report using cocaine at intake.</description>
        <time_frame>baseline to 3 months post 12-week trial period</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Matched placebo pills to be taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>Progesterone: 100mgs progesterone twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse to Cocaine Use During Treatment Period or 3 Months Post Treatment</title>
          <description>Post-hoc sensitivity test to compare hazard of relapse to cocaine use between two treatment groups among participants (n=41) who did not report using cocaine at intake.</description>
          <population>intent-to-treat</population>
          <units>participants who relapsed to cocaine use</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>13.30</ci_upper_limit>
            <estimate_desc>Ratio presented is for placebo versus progesterone</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the entire study period, from the intake of the participants to their final 3-month follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matched placebo pills to be taken twice daily
Placebo: Matched placebo pills to be taken twice daily</description>
        </group>
        <group group_id="E2">
          <title>Progesterone</title>
          <description>100 mgs progesterone twice daily
Progesterone: 100mgs progesterone twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Women seen only once per week leading to reliance on self-reports more than urine, results of which differed; post-partum women with cocaine use disorder have other issues affecting likelihood of cocaine use; missed visits may have biased results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kimberly A. Yonkers, M.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-764-6621</phone>
      <email>kimberly.yonkers@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

